Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 StudyGlobeNewsWire • 02/03/21
Crinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/06/21
Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical EndocrinologyGlobeNewsWire • 11/16/20
Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for the Treatment of AcromegalyGlobeNewsWire • 11/13/20
Should You Buy Crinetics Pharmaceuticals (CRNX) Ahead of Earnings?Zacks Investment Research • 11/09/20
Crinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/06/20
Crinetics Pharmaceuticals Announces Phase 2 ACROBAT Edge Study with Paltusotine in Acromegaly Met Primary EndpointGlobeNewsWire • 10/26/20
Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital HyperinsulinismGlobeNewsWire • 09/21/20
Crinetics Pharmaceuticals Provides New Data from Paltusotine and ACTH Antagonist Development Programs at European Congress of EndocrinologyGlobeNewsWire • 09/04/20
Crinetics Pharmaceuticals Appoints Rare Disease Executive, Camille L. Bedrosian, M.D.GlobeNewsWire • 09/03/20
Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/07/20
Crinetics Pharmaceuticals Receives Orphan Drug Designation for Paltusotine for the Treatment of AcromegalyGlobeNewsWire • 07/08/20
Crinetics Pharmaceuticals, Inc. (CRNX) Shares March Higher, Can It Continue?Zacks Investment Research • 06/19/20
Crinetics Pharmaceuticals Confirms Completion for Half of the Enrolled Patients in the Ongoing Phase 2 ACROBAT Edge Clinical Trial for PaltusotineGlobeNewsWire • 06/11/20
Crinetics Pharmaceuticals Appoints Adriana Cabré, MBA, as Vice President of Human ResourcesGlobeNewsWire • 05/27/20
Is Crinetics Pharmaceuticals (CRNX) Stock a Solid Choice Right Now?Zacks Investment Research • 05/14/20
Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/08/20
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 04/17/20
Crinetics Pharmaceuticals, Inc. (CRNX) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 04/17/20
Crinetics Pharmaceuticals Reports Positive Interim Results for the ACROBAT Edge Phase 2 Trial of Paltusotine (CRN00808) in Acromegaly Patients and Provides Corporate UpdateGlobeNewsWire • 04/06/20
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/12/19